- The FDA approves Roche's (OTCQX:RHHBY) cytomegalovirus (CMV) test specifically targeted to patients who have undergone a hematopoietic stem cell transplant (HSCT). The real-time polymerase chain reaction (PCR)-based assay is designed to use on the company's automated COBAS AmpliPrep/COBAS TaqMan System.
- The test is intended for use as an aid in the management of solid-organ and HSCT recipients who are undergoing anti-CMV therapy. The quantitative test enables serial DNA measurements that can be used to assess virologic response to treatment.